SKYE

Skye Bioscience, Inc.

Price Chart

No historical data available

Latest Quote

$1.77

-0.18 (-8.97%)

Current Price

Previous Close	$1.95
Open	$1.95
Day High	$1.95
Day Low	$1.76
Volume	77,971

Fetched: 2026-08-29T16:20:24

Stock Information

Shares Outstanding	4.43M
Total Debt	$179K
Cash Equivalents	$10.06M
Net Income	$-50.49M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$7.86M
EPS (TTM)	$-10.24
Exchange	NCM

🌐 Visit Website

Recent Price History

No history data available. Data will be fetched automatically.

About Skye Bioscience, Inc.

Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.

📰 Latest News

No news articles available at the moment. Check back later for updates on SKYE.

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Interest Expense	$0	$967,602	$897,207	$663,774
Total Expenses	$58,163,565	$36,427,435	$13,671,801	$12,106,422
Other Income Expense	$360,248	$7,590,929	$-23,163,087	$-6,602,089
Other Non Operating Income Expenses	$-502	$-2,200	$-1,383,282	-
Net Non Operating Interest Income Expense	$1,883,903	$2,279,454	$-806,296	$-766,350
Interest Expense Non Operating	$0	$967,602	$897,207	$663,774
Operating Expense	$58,163,565	$36,427,435	$13,671,801	$12,106,422
General And Administrative Expense	$15,801,686	$17,725,741	$7,852,340	$6,094,617
Total Other Finance Cost	-	$16,456	$9,063	$121,587
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-55,924,814	$-26,567,123	$-37,644,784	$-19,481,602
Net Interest Income	$1,883,903	$2,279,454	$-806,296	$-766,350
Interest Income	$1,883,903	$3,263,512	$99,974	$19,011
Normalized Income	$-56,209,806	$-32,565,695	$-20,438,738	$-14,265,952
Net Income From Continuing And Discontinued Operation	$-55,924,814	$-26,567,123	$-37,644,784	$-19,481,602
Total Operating Income As Reported	$-58,163,565	$-30,192,718	$-34,735,173	$-18,311,732
Net Income Common Stockholders	$-55,924,814	$-26,567,123	$-37,644,784	$-19,481,602
Net Income	$-55,924,814	$-26,567,123	$-37,644,784	$-19,481,602
Net Income Including Noncontrolling Interests	$-55,924,814	$-26,567,123	$-37,644,784	$-19,481,602
Net Income Continuous Operations	$-55,924,814	$-26,567,123	$-37,644,784	$-19,481,602
Pretax Income	$-55,919,414	$-26,557,052	$-37,641,184	$-19,474,861
Special Income Charges	$360,750	$7,593,129	$-21,779,805	$-6,661,818
Interest Income Non Operating	$1,883,903	$3,263,512	$99,974	$19,011
Operating Income	$-58,163,565	$-36,427,435	$-13,671,801	$-12,106,422
Per Share
Diluted EPS	$-1.41	$-0.73	$-5.37	$-8.77
Basic EPS	$-1.41	$-0.73	$-5.37	$-8.77
Other
Tax Effect Of Unusual Items	$75,758	$1,594,557	$-4,573,759	$-1,386,439
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-55,556,812	$-32,883,939	$-14,839,921	$-12,094,000
Total Unusual Items	$360,750	$7,593,129	$-21,779,805	$-6,602,089
Total Unusual Items Excluding Goodwill	$360,750	$7,593,129	$-21,779,805	$-6,602,089
Reconciled Depreciation	$723,352	$298,640	$124,251	$114,998
EBITDA (Bullshit earnings)	$-55,196,062	$-25,290,810	$-36,619,726	$-18,696,089
EBIT	$-55,919,414	$-25,589,450	$-36,743,977	$-18,811,087
Diluted Average Shares	$39,662,664	$36,486,519	$7,006,038	$2,221,080
Basic Average Shares	$39,662,664	$36,486,519	$7,006,038	$2,221,080
Diluted NI Availto Com Stockholders	$-55,924,814	$-26,567,123	$-37,644,784	$-19,481,602
Tax Provision	$5,400	$10,071	$3,600	$6,741
Gain On Sale Of Ppe	$360,750	$1,358,412	$-307,086	$0
Research And Development	$42,361,879	$18,701,694	$5,819,461	$6,011,805
Selling General And Administration	$15,801,686	$17,725,741	$7,852,340	$6,094,617
Other Gand A	$15,801,686	$17,725,741	$7,852,340	$6,094,617
Gain On Sale Of Business	-	$0	$-409,347	$-456,508
Other Special Charges	-	$-6,234,717	$21,063,372	$6,205,310
Restructuring And Mergern Acquisition	-	-	$409,347	$456,508
Gain On Sale Of Security	-	-	$3	$59,729
Write Off	-	-	-	$456,508

Fetched: 2026-08-29

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$20,024,175	$68,151,724	$-2,131,818	$-3,008,054
Total Assets	$28,313,633	$72,763,773	$11,940,411	$9,111,072
Total Non Current Assets	$1,219,486	$1,936,526	$289,568	$167,354
Other Non Current Assets	$53,910	$53,910	$8,309	$8,309
Current Assets	$27,094,147	$70,827,247	$11,650,843	$8,943,718
Other Current Assets	$13,781	$207,205	$558,248	$306,081
Prepaid Assets	$1,332,671	$2,199,236	$597,698	$882,193
Receivables	$10,474	$5,065	$158,242	$74,121
Taxes Receivable	$10,474	$5,065	$158,242	$74,121
Cash Cash Equivalents And Short Term Investments	$25,737,221	$68,415,741	$1,256,453	$1,244,527
Cash And Cash Equivalents	$5,882,498	$68,415,741	$1,256,453	$1,244,527
Restricted Cash	-	$0	$9,080,202	$4,580
Assets Held For Sale Current	-	-	$0	$6,432,216
Cash Financial	-	-	$1,256,453	$1,244,527
Debt
Total Debt	$273,646	$455,590	$4,615,266	$1,982,526
Long Term Debt And Capital Lease Obligation	$83,999	$273,162	$171,230	$0
Current Debt And Capital Lease Obligation	$189,647	$182,428	$4,444,036	$1,982,526
Net Debt	-	-	$3,115,545	$659,299
Current Debt	-	-	$4,371,998	$1,903,826
Other Current Borrowings	-	-	$4,371,998	$1,903,826
Liabilities
Total Liabilities Net Minority Interest	$8,289,458	$4,612,049	$14,072,229	$12,119,126
Total Non Current Liabilities Net Minority Interest	$83,999	$273,162	$171,230	$0
Current Liabilities	$8,205,459	$4,338,887	$13,900,999	$12,119,126
Other Current Liabilities	$2,633,918	$549,149	$969,615	$7,482,850
Payables And Accrued Expenses	$5,381,894	$3,607,310	$8,487,348	$2,653,750
Payables	$2,033,431	$569,252	$956,754	$1,890,748
Accounts Payable	$2,033,431	$569,252	$956,754	$1,794,898
Interest Payable	-	$0	$360,777	$15,814
Other Payable	-	-	-	$55,451
Equity
Common Stock Equity	$20,024,175	$68,151,724	$-2,131,818	$-3,008,054
Total Equity Gross Minority Interest	$20,024,175	$68,151,724	$-2,131,818	$-3,008,054
Stockholders Equity	$20,024,175	$68,151,724	$-2,131,818	$-3,008,054
Retained Earnings	$-186,874,486	$-130,949,672	$-104,382,549	$-66,737,765
Other
Ordinary Shares Number	$33,378,139	$30,974,559	$12,349,243	$3,654,115
Share Issued	$33,378,139	$30,974,559	$12,349,243	$3,654,115
Tangible Book Value	$20,024,175	$68,151,724	$-2,131,818	$-3,008,054
Invested Capital	$20,024,175	$68,151,724	$2,240,180	$-1,104,228
Working Capital	$18,888,688	$66,488,360	$-2,250,156	$-3,175,408
Capital Lease Obligations	$273,646	$455,590	$243,268	$78,700
Total Capitalization	$20,024,175	$68,151,724	$-2,131,818	$-3,008,054
Additional Paid In Capital	$206,865,282	$199,070,421	$102,238,382	$63,726,057
Capital Stock	$33,379	$30,975	$12,349	$3,654
Common Stock	$33,379	$30,975	$12,349	$3,654
Preferred Stock	$0	$0	$0	$0
Long Term Capital Lease Obligation	$83,999	$273,162	$171,230	$0
Current Capital Lease Obligation	$189,647	$182,428	$72,038	$78,700
Current Accrued Expenses	$3,348,463	$3,038,058	$7,530,594	$763,002
Net PPE	$1,165,576	$1,882,616	$281,259	$159,045
Accumulated Depreciation	$-773,647	$-233,513	$-95,434	-
Gross PPE	$1,939,223	$2,116,129	$376,693	$159,045
Leases	$23,918	$23,918	$13,954	-
Other Properties	$266,646	$449,864	$237,983	$71,191
Machinery Furniture Equipment	$1,648,659	$1,642,347	$124,756	-
Properties	$0	$0	$0	$0
Other Short Term Investments	$19,854,723	$0	-	-
Dueto Related Parties Current	-	-	$0	$95,850
Buildings And Improvements	-	-	$43,276	$87,854

Fetched: 2026-08-29

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-43,068,841	$-26,841,507	$-13,964,728	$-12,772,132
Operating Activities
Operating Cash Flow	$-43,062,529	$-25,237,480	$-13,952,178	$-12,744,072
Cash Flow From Continuing Operating Activities	$-43,062,529	$-25,237,480	$-13,952,178	$-12,744,072
Operating Gains Losses	$-360,750	$-1,347,618	$21,472,867	$-59,729
Investing Activities
Capital Expenditure	$-6,312	$-1,604,027	$-12,550	$-28,060
Investing Cash Flow	$-19,500,285	$-245,615	$6,596,456	$5,214,395
Cash Flow From Continuing Investing Activities	$-19,500,285	$-245,615	$6,596,456	$5,214,395
Net Other Investing Changes	-	-	$1,076,740	$5,242,455
Financing Activities
Issuance Of Capital Stock	$0	$83,556,563	$11,734,947	$0
Financing Cash Flow	$29,571	$83,562,181	$16,443,270	$-208,794
Cash Flow From Continuing Financing Activities	$29,571	$83,562,181	$16,443,270	$-208,794
Net Common Stock Issuance	$0	$83,556,563	$11,734,947	$0
Common Stock Issuance	$0	$83,556,563	$11,734,947	$0
Net Other Financing Charges	-	-	$-6,026	-
Other
Interest Paid Supplemental Data	$0	$433,336	$198,352	$333,547
Income Tax Paid Supplemental Data	$5,400	$5,200	$3,600	$6,741
End Cash Position	$5,882,498	$68,415,741	$10,336,655	$1,249,107
Beginning Cash Position	$68,415,741	$10,336,655	$1,249,107	$8,987,578
Changes In Cash	$-62,533,243	$58,079,086	$9,087,548	$-7,738,471
Proceeds From Stock Option Exercised	$29,571	$5,618	$0	$1,967
Net Investment Purchase And Sale	$-19,854,723	$0	-	-
Purchase Of Investment	$-19,854,723	$0	-	-
Net PPE Purchase And Sale	$354,438	$-245,615	$5,519,716	$-28,060
Sale Of PPE	$360,750	$1,358,412	$5,532,266	$0
Purchase Of PPE	$-6,312	$-1,604,027	$-12,550	$-28,060
Change In Working Capital	$4,731,989	$-2,628,758	$-469,307	$-761,904
Change In Other Current Liabilities	$2,126,762	$-438,793	$-665,888	$-1,825,774
Change In Other Current Assets	$1,357,508	$-1,460,826	$-488,790	$112,907
Change In Payables And Accrued Expense	$1,550,647	$-721,436	$-109,861	$953,927
Change In Accrued Expense	$155,219	$-134,903	$591,424	$154,187
Change In Interest Payable	$0	$-360,777	$360,777	$-159,097
Change In Payable	$1,395,428	$-586,533	$-701,285	$799,740
Change In Account Payable	$1,395,428	$-586,533	$-701,285	$799,740
Change In Prepaid Assets	$-302,928	$-7,703	$795,232	$-2,964
Stock Based Compensation	$7,767,694	$8,317,480	$987,510	$629,032
Asset Impairment Charge	$0	$325,610	$0	-
Depreciation Amortization Depletion	$723,352	$298,640	$124,251	$114,998
Depreciation And Amortization	$723,352	$298,640	$124,251	$114,998
Net Income From Continuing Operations	$-55,924,814	$-26,567,123	$-37,644,784	$-19,481,602
Repayment Of Debt	-	$0	$-259,335	$-891,662
Issuance Of Debt	-	$0	$4,973,684	$680,901
Net Issuance Payments Of Debt	-	$0	$4,714,349	$-210,761
Net Short Term Debt Issuance	-	$0	$4,973,684	$0
Short Term Debt Issuance	-	$0	$4,973,684	$0
Net Long Term Debt Issuance	-	$0	$-259,335	$-210,761
Long Term Debt Payments	-	$0	$-259,335	$-891,662
Other Non Cash Items	-	$-3,635,711	$1,577,285	$6,815,133
Net Foreign Currency Exchange Gain Loss	-	$0	$-45,350	$0
Gain Loss On Sale Of PPE	-	$0	$21,215,214	$0
Short Term Debt Payments	-	-	$-6,026	$-616,125
Long Term Debt Issuance	-	-	$0	$680,901
Gain Loss On Investment Securities	-	-	$-3	$-59,729
Change In Other Working Capital	-	-	-	-

Fetched: 2026-08-29